IRIS UniCatt

Bianco, Assunta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.867
EU - Europa 1.883
AS - Asia 1.715
SA - Sud America 361
Continente sconosciuto - Info sul continente non disponibili 101
AF - Africa 37
OC - Oceania 7
Totale 6.971
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.778
SG - Singapore 778
DE - Germania 663
CN - Cina 395
SE - Svezia 292
BR - Brasile 282
IT - Italia 281
VN - Vietnam 156
FR - Francia 152
GB - Regno Unito 106
UA - Ucraina 89
IE - Irlanda 70
IN - India 70
FI - Finlandia 64
HK - Hong Kong 55
ID - Indonesia 48
CA - Canada 45
BD - Bangladesh 42
JP - Giappone 36
RU - Federazione Russa 29
AR - Argentina 28
TR - Turchia 26
IQ - Iraq 24
PL - Polonia 22
AT - Austria 19
BE - Belgio 18
MX - Messico 18
NL - Olanda 17
KR - Corea 15
VE - Venezuela 15
CI - Costa d'Avorio 13
CO - Colombia 13
EC - Ecuador 10
ES - Italia 9
SA - Arabia Saudita 9
IR - Iran 8
JO - Giordania 6
TN - Tunisia 6
CH - Svizzera 5
DO - Repubblica Dominicana 5
IL - Israele 5
LT - Lituania 5
PH - Filippine 5
PK - Pakistan 5
UY - Uruguay 5
AU - Australia 4
CZ - Repubblica Ceca 4
MA - Marocco 4
RO - Romania 4
SK - Slovacchia (Repubblica Slovacca) 4
UZ - Uzbekistan 4
ZA - Sudafrica 4
CL - Cile 3
EE - Estonia 3
HU - Ungheria 3
JM - Giamaica 3
MD - Moldavia 3
MY - Malesia 3
NI - Nicaragua 3
NO - Norvegia 3
NP - Nepal 3
PA - Panama 3
PY - Paraguay 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BG - Bulgaria 2
BH - Bahrain 2
BO - Bolivia 2
BY - Bielorussia 2
CR - Costa Rica 2
EG - Egitto 2
GR - Grecia 2
HN - Honduras 2
HR - Croazia 2
KE - Kenya 2
KG - Kirghizistan 2
LV - Lettonia 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PS - Palestinian Territory 2
PT - Portogallo 2
SN - Senegal 2
AM - Armenia 1
AO - Angola 1
BS - Bahamas 1
CG - Congo 1
DK - Danimarca 1
ET - Etiopia 1
GE - Georgia 1
GT - Guatemala 1
HT - Haiti 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
Totale 6.865
Salva come PNG Salva come JPEG
Città #
Singapore 445
Chandler 319
San Jose 274
Ashburn 250
Frankfurt am Main 124
Beijing 87
New York 75
Ann Arbor 71
Dublin 70
Rome 59
Jacksonville 58
Los Angeles 58
San Mateo 57
Hong Kong 54
Nürnberg 51
Hefei 50
Lauterbourg 50
Ho Chi Minh City 49
Jakarta 47
Milan 46
Hanoi 43
Tokyo 31
Atlanta 30
Boston 29
Munich 29
Nanjing 28
Wilmington 28
Santa Clara 27
São Paulo 26
Chicago 25
Princeton 24
Woodbridge 24
Dallas 22
Dearborn 22
Helsinki 22
Houston 21
Buffalo 20
Moscow 20
Bremen 18
Marseille 18
Brussels 17
Nuremberg 17
Kent 16
Seoul 15
Warsaw 15
Izmir 14
Lappeenranta 14
Orem 14
Pune 14
Abidjan 13
Brooklyn 13
Turku 13
Seattle 12
The Dalles 12
Baghdad 11
Boardman 11
London 11
Norwalk 11
Shanghai 11
Toronto 11
Cattolica 10
Council Bluffs 10
Lawrence 10
Rio de Janeiro 10
Redwood City 9
Vienna 9
Washington 9
Chennai 8
Denver 8
Düsseldorf 8
Haiphong 8
Las Vegas 8
Leawood 8
Mexico City 8
Montreal 8
North Bergen 8
Phoenix 8
San Francisco 8
Amsterdam 7
Detroit 7
Kunming 7
Nanchang 7
Naples 7
Thái Nguyên 7
Tianjin 7
Andover 6
Ankara 6
Da Nang 6
Newark 6
Paris 6
Portsmouth 6
Stockholm 6
Tukwila 6
Amman 5
Belo Horizonte 5
Caracas 5
Changsha 5
Dhaka 5
Elk Grove Village 5
Falkenstein 5
Totale 3.353
Salva come PNG Salva come JPEG
Nome #
The Expanding Role of the Infectious Disease Expert in the Context of the MS Centre 308
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review 301
Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis 268
Second-Line Therapy with Fingolimod for Relapsing-Remitting Multiple Sclerosis in Clinical Practice: The Effect of Previous Exposure to Natalizumab 258
CD8(+) T Cells in Facioscapulohumeral Muscular Dystrophy Patients with Inflammatory Features at Muscle MRI 250
Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant? 245
T-bet, pSTAT1 and pSTAT3 expression in peripheral blood mononuclear cells during pregnancy correlates with post-partum activation of multiple sclerosis. 241
The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing-remitting multiple sclerosis. 195
Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients. 176
Epstein-Barr virus antibodies in serum and cerebrospinal fluid from Multiple Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Amyotrophic Lateral 172
Lambert-Eaton Myasthenic Syndrome associated with gastric schwannoma 171
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 170
Demyelinating Encephalomyeloradiculitis with Balò-like lesions 165
New onset of Susac syndrome after mRNA COVID-19 vaccine: a case report 161
Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients 157
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 154
Increased CD4(+)CD25(+)Foxp3(+) T Cells in Peripheral Blood of Celiac Disease Patients: Correlation with Dietary Treatment. 153
Wash-out duration and lymphocyte count in switching from fingolimod to ofatumumab: A case report and literature review 151
Epidemiology of intensive care unit-acquired sepsis in Italy: Results of the SPIN-UTI network 139
Glioblastoma in multiple sclerosis: a case report 133
Defining the disease course of TNFα blockers-associated Multiple Sclerosis 130
CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis 127
Dominus effect: challenging complications of alemtuzumab-related thyroid autoimmunity 126
Liposome-based nanoparticles impact on regulatory and effector phenotypes of macrophages and T cells in multiple Sclerosis patients 123
Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment 122
Liposome-based nanoparticles impact on regulatory and effector phenotypes of macrophages and T cells in multiple Sclerosis patients 120
Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study 118
Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report 117
Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients 112
The predictive value of CSF multiple assay in multiple sclerosis: A single center experience 112
Fingolimod vs dimethyl fumarate in multiple sclerosis 109
Neurosarcoidosis presenting as longitudinally extensive myelitis: Diagnostic assessment, differential diagnosis, and therapeutic approach 104
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis 100
Cyclophosphamide in highly aggressive Marburg-like multiple sclerosis 96
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 91
Acyclovir-related kidney injury during alemtuzumab infusion 87
The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray) 87
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY) 83
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study 80
Sativex® effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients 80
An early feasibility study for neurological devices: The ARCTRAN study 79
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 79
Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of Frailty 78
A true isolated cognitive relapse in multiple sclerosis 77
The predictive value of CSF multiple assay in multiple sclerosis: A single center experience 76
Moving to fingolimod from natalizumab in multiple sclerosis: the ENIGM is not solved 69
Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod 68
Correction to: Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study (Journal of Neurology, (2022), 269, 3, (1610-1617), 10.1007/s00415-021-10737-w) 66
Clinically relevant increases in serum neurofilament light chain and glial fibrillary acidic protein in patients with Susac syndrome 64
An early feasibility study for neurological devices: The ARCTRAN study 51
IgE-mediated allergic reactions to ocrelizumab in multiple sclerosis: A retrospective cohort study 40
Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian study 38
Paramagnetic Rim Lesions in Highly Active Multiple Sclerosis at the Time of Disease Diagnosis: Prevalence Data and Clinical Implications 25
Childhood trauma and treatment compliance in people with multiple sclerosis: The mediating role of physician-patient rapport 23
Positioning siponimod and the post-treatment gap: the unmet needs of SPMS patients in Italian real-world practice 21
Dynamics of Myelin-Specific T-Cell Repertoires Mirror Disease Activity and Central Nervous System Trafficking in Multiple Sclerosis 11
Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies 11
Pregnancy Exposure to Anti-CD20 Monoclonal Antibodies in Patients With Multiple Sclerosis: Results From an Italian Multicenter Registry Study 3
Totale 6.971
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.719
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.719
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022330 0 0 19 41 13 11 8 55 22 23 54 84
2022/2023856 89 107 60 136 64 113 42 82 96 10 41 16
2023/2024405 18 93 14 20 18 68 35 12 7 20 42 58
2024/2025816 14 24 61 53 44 32 14 26 137 72 185 154
2025/20262.579 321 67 123 247 489 215 424 151 167 199 93 83
2026/2027805 115 586 104 0 0 0 0 0 0 0 0 0
Totale 6.971